MGC Pharmaceuticals Ltd.
| ISIN | 🆔 |
|---|---|
| Industry | Pharmaceuticals and Medical Research |
| Founded 📆 | 2005 |
| Founder 👔 | |
| Headquarters 🏙️ | , Europe and Australia |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | https://mgcpharma.com.au/ |
| 📇 Address | |
| 📞 telephone | |
MGC is an EU based biopharmaceutical company founded in the year 2005 by Roby Zomer. MGC Pharmaceuticals is also known for its trade in ASX under MXC code with core strategy of seed- pharmacy. This company's core business is to develop and supply high-quality cannabinoid-based pharmaceutical products to medical markets in Europe, North America, and Australasia.[1][2]
Overview[edit]
This Firm uses cannabis ingredients (cannabinoids) to treat diseases such as Epilepsy and Dementia. MGC Pharma has collaborated with Royal Melbourne Institute of Technology on a project to oversee cannabis research activities at RMIT.[1][3][4]
MGC Pharmaceuticals has three divisions Pharma, Botanic division and Derma division.
Pharma deals with medical research and development of the company's pharmaceutical products. Botanic deals with the supply of raw material. And Derma deals with the development of cosmetics and tested dermatological products to the companies.[5]
This company published a couple of whitepapers dealing with medical cannabis to treat epilepsy, cancer, and multiple sclerosis. MGC Pharma signed a 5-year, Supply and Distribution Agreement with European pharmaceutical distribution company, Lenis farmacevtika. MGC received legal permission for the sale of marijuana products for medical use in Australia's new market. MGC Pharma sells MGC Derma business to strategic partners with a five year supply agreement for MGC Pharma's cannabidiol(CBD) and cosmetics raw material to Cannaglobal.
Revenue[edit]
MGC sponsored CannaTechUK 2017 held at the Old Truman Brewery in East London's arts and media quarter in October. MGC Pharma added 31.37% to its share price after its CannEpil medical cannabis product received an Australian Therapeutic Goods Administration approval for reimbursement to people with drug-resistant epilepsy. MGC raised over $5 million through a share placement to professional investors at 7 cents per share.[1][6][7]
Awards[edit]
MGC has been awarded a contract by the government of Malta to construct a 4000 square meter state-of-the-art medical cannabis production and cultivation facility.[8][9]
References[edit]
- ↑ 1.0 1.1 1.2 "MGC Pharma receives TGA approval to market epilepsy drug in Australia". www.biospectrumasia.com. Retrieved 2019-08-01.
- ↑ "Nativ Segev". Business News. Retrieved 2019-08-01.
- ↑ "MGC Pharma on track for Europe medical cannabis site". The West Australian. 2017-02-21. Retrieved 2019-08-01.
- ↑ Latimer, Audrey. "CannaGlobal Acquires MGC Derma". Global Cosmetic Industry. Retrieved 2019-08-01.
- ↑ "MGC jumps after securing new European Cannabis license". The West Australian. 2017-06-05. Retrieved 2019-08-01.
- ↑ "MGC Pharmaceuticals Ltd". MarketWatch. Retrieved 2019-08-01.
- ↑ Jalimnson, Gillian (2016-09-22). "Treating Epilepsy, Cancer And MS With Cannabis - Clinical Evidence". Hemp Gazette. Retrieved 2019-08-01.
- ↑ Jalimnson, Gillian (2016-03-29). "White Paper: Medicinal Cannabis in Australia". Hemp Gazette. Retrieved 2019-08-01.
- ↑ Major EU Pharma Supply Agreement Signed with Lenis (PDF). Search this book on
External links[edit]
This article "MGC Pharmaceuticals Ltd" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:MGC Pharmaceuticals Ltd. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
